miRNA-154在星形细胞瘤中的表达及其临床意义

Expression of miRNA-154 in astrocytomas and its clinical significance

目的探讨星形细胞瘤组织和血清中微小RNA-154(miR-154)的表达及其临床意义。方法收集2011年1月至2015年12月手术切除的星形细胞瘤组织76例和癌旁组织36例,采用荧光实时定量PCR(QPCR)法检测上述组织中miR-154的表达水平并比较星形细胞瘤组织及癌旁组织中的表达差异。同时检测49例星形细胞瘤患者术前血清miR-154表达水平,并与52例健康体检者的血清标本作比较;分析29例患者手术前后血清miR-154的表达变化。分析星形细胞瘤组织miR-154表达与临床病理特征(年龄、性别、肿瘤分级和KPS评分)的关系,根据随访资料分析不同miR-154表达患者的预后情况。结果 76例星形细胞瘤组织中miR-154的表达水平为0.254±0.170,低于36例癌旁组织的1.087±0.073,差异有统计学意义(P<0.05);49例星形细胞瘤患者术前血清miR-154的表达水平为0.256±0.180,低于52例健康体检者的1.065±0.350,差异有统计学意义(P<0.05);49例星形细胞瘤患者血清miR-154与组织miR-154表达呈正相关(r=0.552,P=0.000);29例患者术前血清miR-154的表达水平为0.243±0.173,低于术后的0.339±0.159,差异有统计学意义(P<0.05)。星形细胞瘤组织中miR-154表达与性别、年龄及KPS评分无关,但与肿瘤分级有关。全组中位总生存期(OS)为15.7个月,其中miR-154高表达组的中位OS为16.6个月,高于低表达组的11.3个月,差异有统计学意义(P<0.05)。结论 miR-154在星形细胞瘤组织和血清中表达降低,与肿瘤分级有关,且miR-154高表达者的预后较好,可能与星形细胞瘤的发生、发展有关,对星形细胞瘤的诊断和预后评估有一定价值。

Objective To investigate the expression of miR-154 in tissues and sera from patients with astrocytomas and its clinical significance. Methods In this study,76 cases of cerebral astrocytoma and 36 cases of adjacent tissues from January 2011 to December 2015 were collected. Using real-time fluorescence quantitative PCR（ QPCR）,the expression of miR-154 in the above tissues was detected and the distribution of miR-154 in astrocytoma and adjacent tissues was compared. Meanwhile,miR-154 expression of serum samples were also detected in 49 cases of astrocytoma and 52 healthy subjects. The changes of serum level of miR-154 before and after surgery were measured in 29 patients. The relationship of miR-154 expression and common clinical pathological parameters of astrocytoma（ age,gender,tumor grade and KPS score） was investigated. According to the follow-up data,the prognosis of different levels of miR-154 was compared. Results The miR-154 level in 76 cases of astrocytoma tissues was 0. 254 ± 0. 170,lower than1. 087 ± 0. 073 in adjacent tissues,and the difference was statistically significant（ P 〈 0. 05）. The serum miR-154 level of 49 patients was 0. 256 ± 0. 180,less than 1. 065 ± 0. 350 of healthy serum samples,and the difference was statistically significant（ P 〈 0. 05）.The serum level of miR-154 was positively correlated with miR-154 in tissue（ r = 0. 552,P = 0. 000）. The preoperative serum level of miR-154 was 0. 243 ± 0. 173 in 29 patients,lower than 0. 339 ± 0. 159 of postoperative level（ P 〈 0. 05）. In astrocytoma tissues,the expression of miR-154 had no relationship with gender,age and KPS score,but was related with tumor grade. The median overall survival（ OS） of 76 patients was 15. 7 months. The median OS of miR-154 high expression group was 16. 6 months,higher than 11. 3months of low expression group,and the difference was statistically significant（ P 〈 0. 05）. Conclusion The decreased expression of miR-154 is observed in astrocytoma,and is related with tumor grade. Patients with high levels of miR-154 have better prognosis. miR-154 may be related to the occurrence and development of astrocytoma,providing a certain value in the evaluation of diagnosis and prognosis.